TVTX Historical PE Ratio Notes

— Travere Therapeutics (NASDAQ: TVTX) is a biopharmaceutical company focused on developing & commercializing therapies for rare diseases, particularly those affecting the kidney, liver, & metabolic systems. Its lead product, FILSPARI (sparsentan), was approved in 2023 for IgA nephropathy, marking a significant milestone for the company. Historically, TVTX has operated at a loss or with minimal earnings, as is common for companies in the biotech sector who invest heavily in research & development before their drugs are approved & generate significant revenue. As an investor reviewing TVTX's historical P/E ratio, it’s important to recognize that the ratio may often be very high, undefined, or even negative when the company has no earnings or reports losses, reflecting the market's speculation on future profits rather than current earnings. Major milestones, such as clinical trial results or drug approvals, tend to cause fluctuations in the company's valuation, which can influence the P/E ratio even if earnings remain negative or low. When analyzing historical P/E data for TVTX, keep in mind that conventional P/E analysis can be misleading for early-stage biotechs, where valuation often hinges more on future growth potential than on present profitability.

On this page we presented the Travere Therapeutics Historical PE Ratio information for Travere Therapeutics' stock. The average TVTX historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 96.6. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average TVTX historical PE based on this TTM earnings result method is 132.9. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this TVTX historical PE result, against the recent PE: when this page was posted on 6/24/2026, the most recent closing price for TVTX had been 57.69, and the most recent quarterly earnings result, annualized, was 0.2. Meanwhile, the most recent TTM earnings summed to 1.14. From these numbers, we calculate the recent TVTX PE on 6/24/2026 based on annualized quarterly EPS was 288.4. Based on TVTX's history, that recent PE is elevated relative to the historical average, with the recent PE 198.6% higher than the historical average PE across our data set for Travere Therapeutics. Looking at the recent TVTX PE on 6/24/2026 based on TTM EPS, we calculate the ratio at 50.6. Based on TVTX's history, that recent PE is low relative to the historical average, with the recent PE 61.9% lower than the average PE across our Travere Therapeutics data set with TTM EPS used in the calculation at each period.

Another interesting TVTX historical PE Ratio calculation we look at is to take the median earnings per share of the last four quarters for TVTX, and then annualize the resulting value... with that annualized number then being used in the PE calculation. To walk through this math for TVTX, we start with the past four EPS numbers and we first sort them from lowest to highest: 0.05, 0.13, 0.37, and 0.59. We then toss out the highest and lowest result, and then take the average of those two middle numbers — 0.13 and 0.37 — which gives us the median of 0.25. Basically the way to think about this 0.25 number is this: for the trailing four earnings reports, 0.25 marks the "middle ground" number where TVTX has reported a value higher than 0.25 half the time, and has reported a value lower than 0.25 half the time. Annualizing that median value then gets us to 1/share, which we use as the denominator in our next PE calculation. With 57.69 as the numerator (as of 6/24/2026), the calculation is then 57.69 / 1 = 57.7 as the TVTX PE ratio as of 6/24/2026, based on that annualized median value we calculated.

For self directed investors doing their due diligence on TVTX or any other given stock, valuation analysis for TVTX can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Travere Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for TVTX. Thanks for visiting, and the next time you need to research TVTX Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.